Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

NCT05952024 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05952024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05952024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2024
Completion date
April 22, 2029
Enrollment
80 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma